(Total Views: 273)
Posted On: 05/02/2019 6:22:51 PM
Post# of 148903
I finished listening twice to today presentation,
it was very good and very informative , our both doctors are very knowledgeable ...and I learned new important things today.
I will post in this one post my observation..
- 7:00 .......licensing for prognostic test VERY close ..
- 10:00 .....400 patients investigative mono ( so no more 500 )
- 10:20......." we no longer need data from 700 mg dose " ( this was the most important to me )
26 weeks post the first 10 weeks study on 525 mg show 95% efficacy...
( that was a great information , worth entire presentation IMO )
- 13:00....... Dr RP saying :
3 things are regulated by CCR5 ...
1.) make cancer cells to move , metastasize ..
2.) activate DNA repair mechanism ,so cancer becoming resistant to treatment ...
3.) regulate body anti-tumor response..
- 18:00..... lately first studies that shows when we use CCR5 inhibitors we activate body own abilities to kill cancer ,
Its activate anti-tumor immune response.
- 19:40 .... very interesting for couple of minutes DR RP about TNBC,
Patients go threw " liquid biopsy" , before the treatment and 21 days later.
It is a blood test.
They measure CTC and CCR5 on the surface of this cells , they measure them before and during this treatment ,
Very detail planning..
I see Dr RP really want to do a show study here !!!!
I guess he believes in what we have .
- 22:10...measuring of CTC is better indicator for cancer activity than present tests.
High CTC poor prognosis,
Low CTC better prognosis.
- 23:30 .. Top Centers in USA participate in this study.
Q & A
-25 ....Dr NP ,.... going down now to 525 mg in HIV has a positive effect on us ,
( so look that 525 mg will be it for HIV )
-27:00..... Dr R........ in cancer we anticipate 700 mg if well tolerated .
- 29:00 ... DR NP complement Gilead drugs ( looks to me they talking ..
)
it was very good and very informative , our both doctors are very knowledgeable ...and I learned new important things today.
I will post in this one post my observation..
- 7:00 .......licensing for prognostic test VERY close ..
- 10:00 .....400 patients investigative mono ( so no more 500 )
- 10:20......." we no longer need data from 700 mg dose " ( this was the most important to me )
26 weeks post the first 10 weeks study on 525 mg show 95% efficacy...
( that was a great information , worth entire presentation IMO )
- 13:00....... Dr RP saying :
3 things are regulated by CCR5 ...
1.) make cancer cells to move , metastasize ..
2.) activate DNA repair mechanism ,so cancer becoming resistant to treatment ...
3.) regulate body anti-tumor response..
- 18:00..... lately first studies that shows when we use CCR5 inhibitors we activate body own abilities to kill cancer ,
Its activate anti-tumor immune response.
- 19:40 .... very interesting for couple of minutes DR RP about TNBC,
Patients go threw " liquid biopsy" , before the treatment and 21 days later.
It is a blood test.
They measure CTC and CCR5 on the surface of this cells , they measure them before and during this treatment ,
Very detail planning..
I see Dr RP really want to do a show study here !!!!
I guess he believes in what we have .
- 22:10...measuring of CTC is better indicator for cancer activity than present tests.
High CTC poor prognosis,
Low CTC better prognosis.
- 23:30 .. Top Centers in USA participate in this study.
Q & A
-25 ....Dr NP ,.... going down now to 525 mg in HIV has a positive effect on us ,
( so look that 525 mg will be it for HIV )
-27:00..... Dr R........ in cancer we anticipate 700 mg if well tolerated .
- 29:00 ... DR NP complement Gilead drugs ( looks to me they talking ..
) 
(1)
(0)Scroll down for more posts ▼
